Mediastinoscopy for lung cancer
What is a mediastinoscopy?
Doctors use a mediastinoscopy to look inside your chest and at lymph nodes nearby. They can take tissue samples (biopsies).
If tests show you have lung cancer, your specialist usually arranges further tests to find out:
- the size and position of the cancer
- if it has spread outside the lung.
This is called the stage of the cancer. Knowing the stage helps you and your doctor decide on the best treatment for you.
Some of these tests also include taking samples of tissue (biopsies).
A mediastinoscopy is sometimes done instead of an EBUS or EUS. It lets the doctor look at the area in the middle of your chest called the mediastinum and nearby lymph nodes. You have this test under a general anaesthetic. You may need to stay overnight in hospital to have it done.
What happens during a mediastinoscopy?
Related pages
About our information
This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer.
-
References
Below is a sample of the sources used in our lung cancer information. If you would like more information about the sources we use, please contact us at informationproductionteam@macmillan.org.uk
National Institute for Health and Care Excellence (NICE). Lung cancer – Diagnosis and management. Clinical guideline 2019. Last updated 2023. (accessed Nov 2023) Available at: https://www.nice.org.uk/guidance/ng122
European Society for Medical Oncology (ESMO). Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. 2021. (accessed Nov 2023). Available at: https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-lung-and-chest-tumours/small-cell-lung-cancer
European Society for Medical Oncology (ESMO). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. 2017. eUpdate 01 September 2021: New Locally Advanced NSCLC Treatment Recommendations (accessed Nov 2023) Available at: https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-early-stage-and-locally-advanced-non-small-cell-lung-cancer
European Society for Medical Oncology (ESMO). ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. 2022 (accessed Nov 2023). Available at: https://pubmed.ncbi.nlm.nih.gov/35176458/
Date reviewed

Our cancer information meets the PIF TICK quality mark.
This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.
The language we use
We want everyone affected by cancer to feel our information is written for them.
We want our information to be as clear as possible. To do this, we try to:
- use plain English
- explain medical words
- use short sentences
- use illustrations to explain text
- structure the information clearly
- make sure important points are clear.
We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.
You can read more about how we produce our information here.